Brief: Lyra Therapeutics Says Primary Endpoint Met With No Serious Adverse Events Observed

Lyra Therapeutics

12/09/2023 12:07

Sept 12 (Reuters) - Lyra Therapeutics Inc  LYRA.O :
    * LYRA THERAPEUTICS INC - PRIMARY ENDPOINT MET WITH NO
SERIOUS
ADVERSE EVENTS OBSERVED
    * LYRA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM
BEACON
PHASE 2 STUDY OF LYR-220 FOR THE TREATMENT OF CHRONIC
RHINOSINUSITIS (CRS) IN PATIENTS WITH PRIOR ETHMOID SINUS
SURGERY
    * LYRA THERAPEUTICS INC - STATISTICALLY SIGNIFICANT
IMPROVEMENTS
IN EFFICACY WERE OBSERVED AS EARLY AS 2 WEEKS
    * LYRA THERAPEUTICS INC - MOST COMMONLY REPORTED ADVERSE
EVENTS
INCLUDED SINUSITIS, NASOPHARYNGITIS, BRONCHITIS, AND COVID-19

Source text for Eikon:  ID:nGNX6wft4j 
Further company coverage:  LYRA.O 

 ((Reuters.Brief@thomsonreuters.com;))